Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
What strategies do you implement to control the nausea from Enhertu?
Related Questions
Is there any benefit of anastrozole in addition to fulvestrant and palbociclib in a patient with HR+ metastatic breast cancer?
How does the safety profile of Dato-DXd influence its use in patients with comorbidities or frailty compared to standard chemotherapy?
How will you weigh the positive PFS but negative OS benefit when discussing Dato-DXd with patients?
In a patient with metastatic PIK3CA-mutant, HR-positive, HER2-low breast cancer who is intolerant to capivasertib, would you consider treatment with alpelisib plus fulvestrant or with Enhertu?
How do the findings from the INAVO120 trial influence your decision-making process for selecting subsequent lines of therapy in patients who have relapsed after adjuvant CDK4/6 inhibition?
Is there benefit of cold-cap use while patient is on sacituzumab-govitecan?
What treatment would you recommend for a patient with early-stage TNBC treated per KEYNOTE-522, PD-L1 CPS >10, with metastatic recurrence within 12 months of treatment completion?
In what situations would you consider doublet chemotherapy in treatment of a premenopausal de novo metastatic TNBC?
What are your top takeaways in Radiation Oncology from SABCS 2024?
Do you use elacestrant for all patients with metastatic ER+, HER2-, ESR1 mutated breast cancer regardless of duration of response to prior ET+CDK4/6i?
